Diabetes Clinical Trials in Sacramento

View 47 new treatments for Diabetes in Sacramento, CA, and other areas near me, such as Elk Grove, Fairfield, Roseville and Vacaville. Every day, Power helps hundreds of diabetes patients connect with leading medical research.
View 49 trials in Sacramento
Filter (49)

Tirzepatide for Type 2 Diabetes and Obesity

Eli Lilly Clinic, Sacramento + 1 more

The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.Show More

Verified

Recruiting
Phase 2
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

PET Imaging for Fatty Liver Disease

Research Clinic, Sacramento + 1 more

Alzheimer's Disease and related dementias (ADRD) affect about 6 million people in the U.S. and are the fifth leading cause of death for adults over 65. Recent research is investigating how chronic liver diseases like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects one-third of the U.S. population, might influence ADRD through the liver-brain axis. MASLD shares risk factors with Alzheimer's, such as diabetes and hypertension, and studies have linked MASLD to increased risks of cognitive decline and ADRD. Mouse-model studies suggest that chronic liver inflammation in MASLD can induce neuroinflammation and accelerate Alzheimer's pathology, highlighting the importance of studying the liver-brain connection to identify new therapeutic targets for ADRD. The goal of this research is to develop a practical PET imaging method using 18F-FDG to simultaneously assess liver and brain inflammation in patients with MASLD-related ADRD. This approach leverages dynamic FDG-PET scanning and advanced tracer kinetic modeling to quantify glucose transport, overcoming limitations of traditional imaging methods that cannot noninvasively assess chronic liver inflammation. The new method aims to enable comprehensive imaging of liver-brain inflammation crosstalk, validated against the 18F-DPA-714 radiotracer. Success in this project could provide a valuable imaging tool for linking liver inflammation with neuroinflammation and cognitive decline, advancing clinical research and potentially uncovering new pathways for ADRD treatmentShow More
Waitlist

No Placebo Trial

Phase < 1
Est. 6 - 12 Weeks
Guobao Wang, PhD
Principal Investigator

Faricimab for Diabetic Macular Edema

Research Clinic, Sacramento + 1 more

This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.
Recruiting

No Placebo Trial

Phase 4
Est. 5 - 8 Weeks
Dr. Varun Chaudhary, MD, FRCS(C)
Principal Investigator

Tirzepatide for Type 2 Diabetes

Eli Lilly Clinic, Lincoln + 1 more

This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Rifampin for Osteomyelitis in Diabetics

Research Clinic, Sacramento + 1 more

The purpose of this research study is to determine if rifampin, an antibiotic (a medicine that treats infections), is effective in treating osteomyelitis (infection of the bone) of the foot in diabetic patients. Despite use of powerful antibiotics prescribed over a long period of time, many diabetic patients remain at a high risk for needing an amputation of part of the foot or lower leg because the osteomyelitis is not cured. Some small research studies have shown that addition of rifampin to other antibiotics is effective in treating osteomyelitis in both diabetics and non-diabetics. However, because few diabetics with osteomyelitis have been studied, there is no definite proof that it is better than the usual treatments for diabetic patients. If this study finds that adding rifampin to the usual antibiotics prescribed for osteomyelitis reduces the risk for amputations, doctors will be able to more effectively treat many Veteran patients with this serious infection. Improving treatment outcomes is an important healthcare goal of the VA.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
Mary T Bessesen, MD
Study Chair

Faricimab for Diabetic Macular Edema

Genentech Clinic, Sacramento + 1 more

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Clinical Trials
Study Director

Ranibizumab PDS Implant for Diabetic Retinopathy

Hoffmann-La Roche Clinic, Sacramento + 1 more

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator ArmShow More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Clinical Trials
Study Director

New Antibiotics vs Linezolid for Diabetic Foot Infections

MicuRx Clinic, Mather + 1 more

This trial tests a new antibiotic called contezolid, given either through an injection or as a pill, in adults with moderate or severe diabetic foot infections. The antibiotic works by stopping the bacteria from growing.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

Suzetrigine for Diabetic Neuropathy

Vertex Clinic, Sacramento + 1 more

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

Semaglutide for Diabetic Eye Disease

Novo Nordisk Clinic, Sacramento + 2 more

This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Clinical Reporting Anchor and Disclosure (1452)
Study Director
Page 1 of 5

Frequently Asked Questions

How much do diabetes clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do diabetes clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across diabetes trials in Sacramento, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for diabetes patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Sacramento is research being conducted for diabetes?

The University of California Davis Comprehensive Cancer Center in Sacramento is conducting diabetes clinical trials. Additionally, trials are taking place in the central area of the city, with approximately 10 ongoing as of 2024.

What promising new drugs are being tested?

In Sacramento, diabetes research is focusing on treatments like Monoclonal Antibodies and Insulin therapies. Notable specific interventions being studied include Faricimab, Afrezza, and the Dexcom G6 glucose monitoring system.